Ken Fisher
KRYS icon

Ken Fisher’s Krystal Biotech KRYS Stock Holding History

Ken Fisher’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18M Buy
27,784
+23,998
+634% +$6.39M ﹤0.01% 427
2025
Q4 		$933K Buy
+3,786
New +$797K ﹤0.01% 683
2023
Q2 		– Sell
-29
Closed -$2.32K – 1190
2023
Q1 		$2.32K Buy
+29
New +$2.28K ﹤0.01% 1098

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ken Fisher's KRYS Position: Q1 2026 in Review

Ken Fisher increased its Krystal Biotech (KRYS) stake by 634% in Q1 2026, buying an estimated $6.39M and bringing the position to 27,784 shares worth $7.18M. The position accounts for ﹤0.01% of the portfolio, ranked #427.

Ken Fisher first reported a position in KRYS in Q1 2023 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Ken Fisher held 27,784 shares of Krystal Biotech worth $7.18M as of Q1 2026.
  • Ken Fisher bought 23,998 Krystal Biotech shares in Q1 2026, an estimated $6.39M.
  • Krystal Biotech made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #427 holding.
  • Ken Fisher first reported a position in Krystal Biotech in Q1 2023 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.